<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04903626</url>
  </required_header>
  <id_info>
    <org_study_id>M20-350</org_study_id>
    <secondary_id>2020-005777-27</secondary_id>
    <nct_id>NCT04903626</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)</brief_title>
  <official_title>A Multicenter, Single-Arm Prospective Study to Evaluate Safety and Efficacy of GLE/PIB 8-Week Treatment in Adults and Adolescents With Acute Hepatitis C Virus (HCV) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatitis C Virus (HCV) infection is a global health problem. HCV mainly affects liver cells&#xD;
      and causes the liver to become inflamed and damaged. This study will evaluate how safe and&#xD;
      effective glecaprevir/pibrentasvir (GLE/PIB) is in adult and adolescent participants with&#xD;
      acute HCV infection.&#xD;
&#xD;
      GLE/PIB is an approved drug for the treatment of chronic HCV. Around 283 participants at&#xD;
      least 12 years of age with acute HCV Infection will be enrolled in approximately 70 sites&#xD;
      worldwide.&#xD;
&#xD;
      Participants will receive oral tablets of GLE/PIB once daily (QD) for 8 weeks and will be&#xD;
      followed for 12 weeks after the end of treatment.&#xD;
&#xD;
      There may be higher treatment burden for participants in this trial compared to their&#xD;
      standard of care. Participants will attend regular visits during the study at a hospital or&#xD;
      clinic. The effect of the treatment will be checked by medical assessments, blood tests,&#xD;
      monitoring for side effects and completing questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 24, 2021</start_date>
  <completion_date type="Anticipated">April 5, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 5, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Sustained Virological Response 12 Weeks Post-treatment (SVR12) in the Intention-to-Treat (ITT) Population</measure>
    <time_frame>12 weeks after last dose of study drug (Week 20)</time_frame>
    <description>SVR12 is defined as the hepatitis C virus (HCV) ribonucleic acid (RNA) level less than the lower limit of quantification (&lt;LLOQ) 12 weeks after the last dose of the study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-Treatment (SVR12) in the Modified ITT-Virologic Failure (mITT-VF) Population.</measure>
    <time_frame>12 weeks after last dose of study drug (Week 20)</time_frame>
    <description>SVR12 is defined as the hepatitis C virus (HCV) ribonucleic acid (RNA) level less than the lower limit of quantification (&lt;LLOQ) 12 weeks after the last dose of the study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With On-Treatment Virologic Failure in the ITT Population</measure>
    <time_frame>Up to week 8</time_frame>
    <description>On-treatment virologic failure is defined as confirmed increase in HCV RNA of &gt; 1 log10 IU/mL above nadir during treatment, confirmed HCV RNA &gt;= 100 IU/mL after HCV RNA &lt; lower limit of quantification (LLOQ) during treatment, or HCV RNA &gt;= LLOQ at the end of treatment (EOT) with at least 6 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Post-Treatment Relapse in the ITT Population</measure>
    <time_frame>Up to 12 weeks after the last dose of study drug (Week 20)</time_frame>
    <description>Post-treatment (PT) relapse is defined as confirmed HCV RNA &gt;= LLOQ between the end of treatment (EOT) and 12 weeks after the last dose of study drug among participants who completed treatment as planned with HCV RNA &lt; LLOQ at the EOT and with at least 1 PT HCV RNA value, excluding cases of reinfection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Post-Treatment Reinfection With HCV in the ITT Population</measure>
    <time_frame>Up to 12 weeks after the last dose of study drug (Week 20)</time_frame>
    <description>Post-treatment (PT) reinfection is defined as confirmed HCV RNA &gt;= LLOQ in the PT period along with the PT detection of a different HCV genotype, subtype, or clade compared with baseline.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">283</enrollment>
  <condition>Hepatitis C Virus (HCV)</condition>
  <arm_group>
    <arm_group_label>Participants Treated With Glecaprevir/Pibrentasvir for 8 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants treated once daily with oral tablets of glecaprevir/pibrentasvir for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glecaprevir/Pibrentasvir (GLE/PIB)</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Participants Treated With Glecaprevir/Pibrentasvir for 8 weeks</arm_group_label>
    <other_name>ABT-493/ABT-530</other_name>
    <other_name>Mavyret</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Evidence of acute Hepatitis C Virus (HCV) infection prior to enrollment, defined as a&#xD;
             physician diagnosis of acute HCV infection with at least 1 of the following:&#xD;
&#xD;
               -  Negative anti-HCV antibody, HCV Ribonucleic Acid (RNA) and/or HCV core antigen&#xD;
                  followed by a positive HCV RNA or HCV core antigen all within an 8-month period&#xD;
                  prior to screening; OR&#xD;
&#xD;
               -  Negative anti-HCV antibody, HCV RNA and/or HCV core antigen followed by a&#xD;
                  positive HCV RNA or HCV core antigen all within an 11-month period prior to&#xD;
                  screening; AND risk behavior for HCV infection within 6 months prior to positive&#xD;
                  HCV RNA or HCV core antigen; OR&#xD;
&#xD;
               -  Clinical signs and symptoms compatible with acute hepatitis [Alanine&#xD;
                  aminotransferase (ALT) &gt; 5 × upper limit of normal (ULN) and/or jaundice] in the&#xD;
                  absence of a history of chronic liver disease or other cause of acute hepatitis&#xD;
                  and positive HCV RNA or HCV core antigen all within an 8-month period prior to&#xD;
                  screening; AND risk behavior for HCV infection within 6 months prior to positive&#xD;
                  HCV RNA or HCV core antigen; OR&#xD;
&#xD;
               -  Negative anti-HCV antibody with a positive HCV RNA or HCV core antigen within a&#xD;
                  5-month period prior to screening.&#xD;
&#xD;
          -  Absence of hepatocellular carcinoma (HCC) for participants with cirrhosis as indicated&#xD;
             by a negative ultrasound, computed tomography (CT) scan or magnetic resonance imaging&#xD;
             (MRI) within 3 months prior to screening or a negative ultrasound at screening.&#xD;
             Participant who has a positive ultrasound result suspicious of HCC followed by a&#xD;
             subsequent negative CT scan or MRI or biopsy result will be eligible for the study.&#xD;
&#xD;
          -  Participants documented as having no cirrhosis or as having compensated cirrhosis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with prior treatment, including interferon for this HCV infection.&#xD;
&#xD;
          -  History of liver decompensation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Health Research /ID# 233558</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85225-2906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Institute for Liver Health /ID# 228427</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research Chula Vista /ID# 238352</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911-6658</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>TLC Clinical Research Inc /ID# 232334</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, Davis Comprehensive Cancer Center /ID# 230814</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>S California Liver Center /ID# 232336</name>
      <address>
        <city>San Clemente</city>
        <state>California</state>
        <zip>92673</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Angels Clinical Research Institute /ID# 234090</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33122-1713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Midway Immunology and Research /ID# 229194</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Midland Research Group, Inc /ID# 231885</name>
      <address>
        <city>Oakland Park</city>
        <state>Florida</state>
        <zip>33334-4434</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center /ID# 229839</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital /ID# 228930</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Triple O Research Institute /ID# 229928</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407-3100</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Medical Clinic /ID# 233489</name>
      <address>
        <city>Zephyrhills</city>
        <state>Florida</state>
        <zip>33542</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University /ID# 229927</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics /ID# 226934</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Chandler Medical Center /ID# 231588</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Louisville Research Foundation Inc /ID# 232139</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202-1821</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center /ID# 226937</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University /ID# 230694</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System /ID# 226932</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center /ID# 232620</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216-4500</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erie County Medical Center /ID# 230184</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College /ID# 230815</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cumberland Research Assoc /ID# 233233</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atrium Health - Huntersville /ID# 238365</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078-7135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital /ID# 231204</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati /ID# 226922</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0585</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ohio State University /ID# 228484</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cherokee Nation Outpatient Health Center /ID# 232618</name>
      <address>
        <city>Tahlequah</city>
        <state>Oklahoma</state>
        <zip>74464-0545</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University /ID# 232624</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107-4414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Gastroenterology /ID# 233332</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Liver Associates of Texas, P.A /ID# 229775</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2783</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Digestive and Liver Disease Sp /ID# 232633</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin - Plank Rd /ID# 230116</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-3548</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital /ID# 227167</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alfred Health /ID# 227169</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum St. Poelten /ID# 227098</name>
      <address>
        <city>Sankt Poelten</city>
        <state>Niederoesterreich</state>
        <zip>3100</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ordensklinikum Linz GmbH Barmherzige Schwestern /ID# 226985</name>
      <address>
        <city>Linz</city>
        <state>Oberoesterreich</state>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitaet Wien /ID# 226938</name>
      <address>
        <city>Vienna</city>
        <state>Wien</state>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinik Ottakring /ID# 227141</name>
      <address>
        <city>Vienna</city>
        <state>Wien</state>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vancouver Infectious Diseases Centre /ID# 227125</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2C7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charlton Medical Centre /ID# 228100</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Riverdale Community Health Centre /ID# 228098</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4M 3P3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital / McGill University Health Centre /ID# 227126</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier - Hôpital Saint Eloi /ID# 229083</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <state>Herault</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>HCL - Hopital de la Croix-Rousse /ID# 229077</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hopital Saint-Antoine /ID# 229070</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH de Tourcoing /ID# 233732</name>
      <address>
        <city>TOURCOING Cedex</city>
        <zip>59208</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>zibp-Zentrum fuer Infektiologie /ID# 226765</name>
      <address>
        <city>Berlin</city>
        <zip>10439</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Bonn /ID# 226764</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Infektiologikum /ID# 226880</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ICH Study Center GmbH &amp; Co KG /ID# 228162</name>
      <address>
        <city>Hamburg</city>
        <zip>20146</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar - Technische Universitaet Muenchen /ID# 226783</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione PTV Policlinico Tor Vergata /ID# 227078</name>
      <address>
        <city>Rome</city>
        <state>Roma</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O.U. di Bologna Policlinico S.Orsola-Malpighi /ID# 227080</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Ospedali Riuniti /ID# 227081</name>
      <address>
        <city>Foggia</city>
        <zip>71122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda /ID# 227079</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Federico II /ID# 227183</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trias i Pujol /ID# 226698</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Parc de Salut del Mar /ID# 226696</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona /ID# 226695</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Sanitario Sandoval /ID# 226954</name>
      <address>
        <city>Madrid</city>
        <zip>28010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia /ID# 226709</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.rxabbvie.com/</url>
    <description>This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 24, 2021</study_first_submitted>
  <study_first_submitted_qc>May 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute HCV Infection</keyword>
  <keyword>HCV Genotype 1-6</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Glecaprevir/Pibrentasvir</keyword>
  <keyword>ABT-493/ABT-530</keyword>
  <keyword>Mavyret</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>For details on when studies are available for sharing, please refer to the link below.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/abbvie/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

